Literature DB >> 23405517

Time to sputum conversion in smear positive pulmonary TB patients on category I DOTS and factors delaying it.

Raunak Parikh1, Gita Nataraj, Swapna Kanade, Vijay Khatri, Preeti Mehta.   

Abstract

BACKGROUND: Sputum smear positive pulmonary tuberculosis patients expel infectious viable bacilli for a period following commencement of treatment. Patients on Directly Observed Treatment Shortcourse (DOTS) receive intermittent therapy with multidrug regimen. AIMS: To determine the time to sputum smear and culture conversion following initiation of DOTS treatment and study the factors that influence it.
METHODS: A prospective study was undertaken at a tertiary care teaching hospital in Mumbai over a one year period on a cohort of 71 sputum smear positive patients on Category I DOTS treatment. Patients were followed up weekly for upto 20 weeks or until they underwent smear and culture conversion whichever was earlier. At each follow up, specimens were collected and processed for microscopy and culture using standard protocol.
RESULTS: 60/71 [84.55%] patients completed the study. 56/60 [93.3%] patients underwent sputum smear and culture conversion. The median time to smear and culture conversion was end of 5th week [day 35] and 6 1/2 weeks [day 45] respectively. Univariate and stepwise regression analysis showed that patients who had cavitatory disease, high pretreatment smear grade and a past history of tuberculosis were more likely to undergo delayed or nonconversion [P < 0.05].
CONCLUSION: The time to sputum smear and culture conversion under DOTS is similar to previous antituberculosis regimens. Since viable bacilli continue to be expelled for upto two months, infection control measures should be maintained for such time. Patients with cavitatory disease, high pretreatment smear grade or a past history of tuberculosis need to be monitored more closely.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23405517

Source DB:  PubMed          Journal:  J Assoc Physicians India        ISSN: 0004-5772


  23 in total

1.  Profile of tuberculosis patients with delayed sputum smear conversion in the Pacific island of Vanuatu.

Authors:  S Fanai; K Viney; L Tarivonda; C Roseveare; M Tagaro; B J Marais
Journal:  Public Health Action       Date:  2014-06-21

2.  Delayed Sputum Culture Conversion in Tuberculosis-Human Immunodeficiency Virus-Coinfected Patients With Low Isoniazid and Rifampicin Concentrations.

Authors:  Christine Sekaggya-Wiltshire; Amrei von Braun; Mohammed Lamorde; Bruno Ledergerber; Allan Buzibye; Lars Henning; Joseph Musaazi; Ursula Gutteck; Paolo Denti; Miné de Kock; Alexander Jetter; Pauline Byakika-Kibwika; Nadia Eberhard; Joshua Matovu; Moses Joloba; Daniel Muller; Yukari C Manabe; Moses R Kamya; Natascia Corti; Andrew Kambugu; Barbara Castelnuovo; Jan S Fehr
Journal:  Clin Infect Dis       Date:  2018-08-16       Impact factor: 9.079

3.  Daily adjunctive therapy with vitamin D3 and phenylbutyrate supports clinical recovery from pulmonary tuberculosis: a randomized controlled trial in Ethiopia.

Authors:  A Bekele; N Gebreselassie; S Ashenafi; E Kassa; G Aseffa; W Amogne; M Getachew; A Aseffa; A Worku; R Raqib; B Agerberth; U Hammar; P Bergman; G Aderaye; J Andersson; S Brighenti
Journal:  J Intern Med       Date:  2018-05-23       Impact factor: 8.989

4.  Role of Anaemia and Magnesium Levels at the Initiation of Tuberculosis Therapy with Sputum Conversion among Pulmonary Tuberculosis Patients.

Authors:  Yuthika Agrawal; Vipin Goyal; Abhishek Singh; Sandhya Lal
Journal:  J Clin Diagn Res       Date:  2017-06-01

5.  Delay in sputum smear conversion and outcomes of smear-positive tuberculosis patients: a retrospective cohort study in Bafoussam, Cameroon.

Authors:  Fabrice Nembot Djouma; Michel Noubom; Jérôme Ateudjieu; Hubert Donfack
Journal:  BMC Infect Dis       Date:  2015-03-21       Impact factor: 3.090

6.  Time to Sputum Smear Conversion in Smear-Positive Pulmonary Tuberculosis Patients and Factors for Delayed Conversion.

Authors:  Zohreh Azarkar; Gholamreza Sharifzadeh; Azade Ebrahimzadeh; Saeeid Olumi
Journal:  Iran J Med Sci       Date:  2016-01

7.  A prospective, observational study of adverse reactions to drug regimen for multi-drug resistant pulmonary tuberculosis in central India.

Authors:  Rohan Hire; A S Kale; G N Dakhale; Nilesh Gaikwad
Journal:  Mediterr J Hematol Infect Dis       Date:  2014-09-01       Impact factor: 2.576

8.  Baseline Xpert MTB/RIF ct values predict sputum conversion during the intensive phase of anti-TB treatment in HIV infected patients in Kampala, Uganda: a retrospective study.

Authors:  Juliet Namugenyi; Joseph Musaazi; Achilles Katamba; Joan Kalyango; Emmanuel Sendaula; Andrew Kambugu; Jan Fehr; Barbara Castelnouvo; Yukari C Manabe; Willy Ssengooba; Christine Sekaggya-Wiltshire
Journal:  BMC Infect Dis       Date:  2021-06-01       Impact factor: 3.090

9.  Anemia at the initiation of tuberculosis therapy is associated with delayed sputum conversion among pulmonary tuberculosis patients in Dar-es-Salaam, Tanzania.

Authors:  Tumaini J Nagu; Donna Spiegelman; Ellen Hertzmark; Said Aboud; Julie Makani; Mecky I Matee; Wafaie Fawzi; Ferdinand Mugusi
Journal:  PLoS One       Date:  2014-03-18       Impact factor: 3.240

10.  High incidence of tuberculosis, low sensitivity of current diagnostic scheme and prolonged culture positivity in four colombian prisons. A cohort study.

Authors:  Zulma Vanessa Rueda; Lucelly López; Lázaro A Vélez; Diana Marín; Margarita Rosa Giraldo; Henry Pulido; Luis Carlos Orozco; Fernando Montes; María Patricia Arbeláez
Journal:  PLoS One       Date:  2013-11-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.